⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor
globenewswire.com
JNJ
Los Angeles Jury Delivers $40 Million Verdict Against Johnson & Johnson in Talcum Powder Ovarian Cancer Trial
prnewswire.com
JNJ
Chemotherapy Induced Anemia Market Intelligence Report 2025-2032, Featuring Amgen, Johnson & Johnson, Pfizer, Biocon, Intas Pharmaceuticals, Viatris and More - ResearchAndMarkets.com
businesswire.com
AMGN
JNJ
PFE
VTRS
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
prnewswire.com
JNJ
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
prnewswire.com
JNJ
Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Novel Therapy Adoption Landscape | DelveInsight
prnewswire.com
ABBV
JNJ
LLY
MRK
PFE
ABVX
BTK Inhibitors Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
PFE
SNY
TSEM
JNJ
LLY
MRK
BMY
ABBV
GILD
CRSP
NKTR
INCY
United States Multiple Myeloma Market Report: Growth Drivers and Challenges 2025-2033
globenewswire.com
ABBV
JNJ
PFE
BMY
Beispiellose Ergebnisse der Phase III Studie MajesTEC-3 sprechen für TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) in subkutaner Formulierung als potenzieller Behandlungsstandard bereits in der Zweitlinienbehandlung für Patienten mit
globenewswire.com
JNJ
Disease-Modifying Therapies Market to Surpass USD 112.6 Billion by 2033 as Biologic Innovation Redefines Long-Term Disease Control
prnewswire.com
JNJ
ABBV
AZN
GSK
AMGN